Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
July 2015
Click for full info +Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
![]() | 17 July 2015 |
In this Press Release:
Health Risk(s):HIV
Product Type(s):Other or N/A
Topic(s):Advocacy Funding
Full Info:
Resource Type:
Citation:
(2015, July 17). AVAC.
Authors:
[no authors listed]
Health Risks(s):
- HIV
Product type(s):
- Microbicide
- MPTs
- Vaccines
Topic(s):
- Advocacy
- Funding
URL of resource: